Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 9, 992-998, October 2006; doi:10.1634/theoncologist.11-9-992
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Dwyer, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Dwyer, P. J.

Special Section on Colorectal Cancer

The Present and Future of Angiogenesis-Directed Treatments of Colorectal Cancer

Peter J. O’Dwyer

Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Key Words. Angiogenesis • Antiangiogenic • Antibody • Bevacizumab • Colorectal cancer

Correspondence: Peter J. O’Dwyer, M.D., Abramson Cancer Center, University of Pennsylvania, 51 N 39th Street, MAB-103, Philadelphia, Pennsylvania 19104, USA. Telephone: 215-662-8636; e-mail:peter.odwyer{at}uphs.upenn.edu

The level of angiogenic activity in colorectal tumors has been shown to be a determinant of survival. Recent trials established that, in both the first- and second-line treatment of metastatic colorectal cancer, the addition of the vascular endothelial growth factor (VEGF)–directed antibody bevacizumab to chemotherapy significantly prolongs survival compared to chemotherapy alone. Those trials provided proof of principle that inhibition of angiogenesis has the potential to enhance the effectiveness of treatment of this disease. Oral agents directed toward VEGF receptor signaling are in advanced development, but none to date has proven beneficial in phase III trials in advanced colorectal cancer. Additional trials are needed to determine if improved pharmacological characteristics of the small molecules can be modified to replicate the activity of the antibody or if mechanistic differences require a more specific approach. Since bevacizumab has minimal activity as a single agent, a key question for future therapeutic development relates to the interaction between antiangiogenic strategies and cytotoxic therapies. We hypothesize that bevacizumab may potentiate the efficacy of cytotoxics not solely by alterations of tumor interstitial pressure but also by promoting sensitivity to proapoptotic signals consequent upon nutrient and oxygen withdrawal.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
N. T. Fernando, M. Koch, C. Rothrock, L. K. Gollogly, P. A. D'Amore, S. Ryeom, and S. S. Yoon
Tumor Escape from Endogenous, Extracellular Matrix-Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors
Clin. Cancer Res., March 1, 2008; 14(5): 1529 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
The Colorectal Cancer Coalition: Reflections on the Future
Oncologist, October 1, 2006; 11(9): 970 - 972.
[Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement